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has been conducted in a rigorous manner and that linguistic validation interviews have 
been conducted in the target country. The objective of this study was to ascertain 
whether there are particular areas of concern with respect to using these PROs outside 
of North America and Western Europe. METHODS: Specialists in outcomes research 
from nine countries within Eastern Europe, Asia and Africa completed a questionnaire 
and interview about difﬁculties which occur with the cultural relevance of concepts 
included in PROs and other health questionnaires. RESULTS: Numerous cultural and 
linguistic issues became apparent, including: 1)The concept of witchcraft is particu-
larly important in many places in Africa; 2)Japanese people have a tendency to be 
more positive about their disease or emotional health which may affect their responses 
to measures; 3)the concept of family is much more important in some countries, e.g. 
Malaysia and Ukraine; 4) the idea of ‘God’s will’ is particularly important to the way 
people think about health in Saudi Arabia and Sudan; 5)In Saudi Arabia and Sudan 
women rarely play sports (a topic sometimes included in PRO measures); and ques-
tions about alcohol use cannot be used in Islamic countries. CONCLUSIONS: A 
number of issues should be considered during the sequential development of PRO 
measures. This can be achieved using an extended translatability check which would 
include representatives from countries outside of North America and Western Europe 
to help bridge the gap between the cultural speciﬁcity of a sequentially developed 
measure and a cross-culturally developed measure.
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QUALITATIVE METHODS IN PRO RESEARCH: DEVELOPMENT OF A 
METHODS MATRIX
Nixon A, Wild D
Oxford Outcomes Ltd, Oxford, UK
OBJECTIVES: Qualitative research methods are pivotal to PRO research and the 
importance of these methods has been highlighted by the FDA draft guidance. The 
objective of this study was to conduct a review of qualitative methods used in health 
and social research, to evaluate the methods for application in PRO research, and to 
develop a methods matrix to enable the selection of the most appropriate methods in 
a given situation. METHODS: A search was conducted in Medline to identify methods 
of qualitative data collection and analysis in general, and to identify those methods 
applied to PRO research since the publication of the FDA draft guidance in February 
2006. Qualitative research methods falling were evaluated according to the require-
ments for valid and reliable PRO research and a methods matrix was prepared. 
RESULTS: There are a wide variety of methods utilised in health and social research, 
which are in the broad category of qualitative methods for data collection and analysis. 
With some approaches, e.g. thematic analysis and grounded theory, there is a need 
for a tightening of deﬁnition in order to reduce some of the ambiguity around methods. 
In PRO research qualitative methods are used in concept exploration, selection of 
PROs, translation of PROs, migration from paper to ePRO, and development/modi-
ﬁcation of PROs (content validity evidence) among other areas. The results matrix 
identiﬁes which qualitative methods are the most appropriate for use in speciﬁc areas 
of PRO research. CONCLUSIONS: The ways in which qualitative research methods 
are applied in PRO research are varied, with some emergence in recent years of alterna-
tive theoretical approaches. The results matrix provides a useful and practical refer-
ence to enable selection of a range of qualitative methods for application to solve 
speciﬁc PRO research requirements.
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THE ADVANTAGES OF A CENTRALIZED DISSEMINATION STRATEGY 
FOR HEALTH OUTCOMES INSTRUMENTS AND THEIR TRANSLATIONS: 
A CASE EXAMPLE WITH THE ZARIT BURDEN INTERVIEW (ZBI)
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OBJECTIVES: Since December 2007 the Zarit Burden Interview is centrally distrib-
uted under the control and with the collaboration of its developer. Our objective was 
to demonstrate the efﬁcacy of such process by comparing the information about the 
instrument translations retrieved through a classical literature search with the one 
provided through the centralized distribution process. METHODS: We searched 
Medline, Embase and PsychInfo with the keywords: Zarit, caregiver, burden, inter-
view, translation, language, and validation. The articles were tabulated according to 
the language used in the study, the country of reference, and the number of teams in 
each country using the ZBI. The search procedure and the information retrieved were 
then compared with those obtained through the distribution centre. RESULTS: The 
literature search resulted in 106 articles of which 15 concerned ZBI derivatives, and 
9 the original US version. Out of the remaining papers, we identiﬁed 59 local teams 
corresponding to 20 countries and 12 languages. Only 9 articles concerned the psy-
chometric validation of the ZBI in different countries. For most countries, there was 
no way to check item correspondence across translations or to identify whether one 
version was the same one used across all teams, increasing the doubt of having multiple 
translations for one country and language (e.g. Spain—n  9 teams). There was no 
clear information about the translations’ validation status. Contrarily, the information 
provided through the distribution center led to the quick identiﬁcation of 33 transla-
tions, certiﬁed by the developer. Information about copyright, conditions of use and 
methodology of translation was provided. CONCLUSIONS: Findings indicate that 
information retrieved through a centralized distribution is more reliable and less time 
consuming than a search using classical tools. Promoting a controlled centralized 
system with instrument developers’ input will facilitate access to comprehensive infor-
mation, and will contribute to meet health authorities’ requirements of evidence-based 
information.
PMC67
LINGUISTIC ADAPTATION OF THE TREATMENT SATISFACTION WITH 
MEDICINES QUESTIONNAIRE (SATMED-Q) INTO ENGLISH
Ruiz MA1, Rejas J2, Pardo A1, Soto J2
1Universidad Autónoma de Madrid, Madrid, Spain, 2Pﬁzer Spain, Madrid, Spain
OBJECTIVES: Treatment Satisfaction (SATMED-Q) is a generic PRO instrument 
measuring Treatment satisfaction with medicines in chronic health conditions, origi-
nally developed in Spanish, with known good psychometric properties. A new English 
version has been produced and linguistically tested. METHODS: The original version 
was translated into English by the Spanish speaking authors and used as reference 
for further versions. Two independent English native translators created two trans-
lated versions and a harmonised version was produced. The harmonized version 
was tested by three clinicians in a pilot sample of 20 chronic patients. Suggested 
modiﬁcations were introduced and a ﬁnal version was shaped. The ﬁnal version was 
compared with the reference translation and back-translated into Spanish by two other 
independent translators native in Spanish. RESULTS: Meaningful differences were 
found between the two translations, especially when referring to undesirable effects, 
medication-treatment, disease-illness-medical condition, leisure and labour. Slight dif-      
ferences were also found on the words used to anchor the Likert response scales. 
Suggestions from the pilot sample advised to introduce examples accompanying ques-
tions about physical activity, free time activities, daily activities and personal hygiene, 
in order to illustrate questions. Nevertheless, the questionnaire was found easy to 
answer and to understand, and completion times were similar to those found with 
the original instrument. CONCLUSIONS: An English version of the SATMED-Q 
questionnaire is now available with linguistic validity ensured. Although psychometric 
properties should now be assessed, this new version allows beginning the cultural 
validation process and can be safely used as a bridge instrument towards other 
languages.
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CORRELATION BETWEEN ADHERENCE RATES MEASURED BY 
MEDICATION EVENT MANAGEMENT SYSTEM AND SELF-REPORTED 
QUESTIONNAIRES: A META-ANALYSIS
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OBJECTIVES: This study performed meta-analysis examining the correlations of 
measurements of medication adherence (medication event monitoring system [MEMS] 
and self-reported questionnaires) using published study reports. METHODS: The lit-
erature search was performed from 1980–2009 using PubMed, PubMed In Process 
and Non-Indexed, OVID MEDLINE, PsycINFO (EBSCO), CINAHL (EBSCO), OVID 
HealthStar, EMBASE (Elsevier), and Cochrane Databases. The following search terms 
were used: patient compliance, medication adherence, treatment compliance, drug 
monitoring, drug therapy, electronic, digital, computer, monitor, monitoring, drug, 
drugs, pharmaceutical preparations, compliance, and medications. Studies were 
included if the correlation coefﬁcients [Pearson correlation coefﬁcient (rp) or Spearman 
rank correlation coefﬁcient (rs)] between adherences measured by both MEMS and 
self-reported questionnaires were available or could be calculated. A meta-analysis 
was conducted to pool the correlation coefﬁcients using random-effect model. 
RESULTS: A total of 11 studies (N  1684 patients) met the inclusion criteria. The 
mean of adherence measured by MEMS was 74.9%, ranging from 53.4% to 92.9% 
and 84.0% by self-reported questionnaire, from 76.5% to 93.5%. The correlation 
between adherence measured by MEMS and self-report questionnaires ranged from 
0.24 to 0.87. Seven (63.6%) articles reported rp values whereas 4 studies (36.4%) had 
rs values. The combined effect size for 11 studies was 0.45 (p  0.001, 95% conﬁdence 
interval [95% CI]: 0.34–0.56). The subgroup meta-analysis on the studies reporting 
rp and rs correlation revealed the effect size 0.46 (p  0.001, 95% CI: 0.33–0.59) and 
0.43 (p  0.001, 95% CI: 0.23–0.64), respectively. CONCLUSIONS: The correlation 
between adherence measured by MEMS and self-reported questionnaires tends to be 
moderate. Therefore, self-reported questionnaires give good estimate of patient medi-
cation adherence. However, MEMS and self-reported questionnaire should be used 
complementary to get accurate measure for patient adherence.
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EXAMINING MASLOW’S HIERARCHICAL THEORY OF NEEDS BY USING 
THE ITEMS OF THE WHOQOL-BREF
Yao G, Lin WL
National Taiwan University, Taipei, Taiwan
OBJECTIVES: Over the last few decades, many theories have been developed for the 
basic needs of human beings. Speciﬁcally, Maslow’s hierarchical model offered a 
sounder theoretical basis for theory of needs. The aim of this research was to examine 
whether the items of quality of life (based on the WHOQOL-BREF Taiwan version)             
ﬁt with the framework of Maslow’s hierarchy of needs. METHODS: This study used   
13,008 participants aged from 20 to 65 from the 2001 National Health Interview 
Survey (NHIS) in Taiwan. The items of the WHOQOL-BREF were categorized accord-
ing to Maslow’s ﬁve hierarchical levels of needs: physiological needs, safety needs,    
love and belonging needs, esteem needs and self-actualization needs. Structural equa- 
tion modeling (SEM) was conducted to test the hierarchical model. RESULTS: The 
results showed that the model of Maslow’s hierarchy of needs did not ﬁt the real data 
well if all of the items of the WHOQOL-BREF Taiwan version were used. However,     
after deleting several misﬁt items, the model can be ﬁtted well. In general, the deleted           
items were comparatively far from the deﬁnition of Maslow’s hiererchical model. 
CONCLUSIONS: The study showed that partial items from the WHOQOL-BREF ﬁt          
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with the framework of Maslow’s hierarchy of needs. In conclusion, Maslow’s hierar-
chy of needs was partially supported by the WHOQOL-BREF.
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CLASSIFYING PATIENT REPORTED OUTCOMES: DEVELOPMENTS IN 
THE FIELD SUGGEST A NEW TAXONOMY
Lloyd A1, Bridges JF2, Johnson FR3
1Oxford Outcomes Ltd, Oxford, UK, 2Johns Hopkins University, Bloomberg School of Public 
Health, Baltimore, MD, USA, 3RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: The FDA proposed the term ‘patient reported outcomes’ in 2001 which 
grouped concepts such as quality of life (HRQL), satisfaction and preference together 
in terms of their role in regulatory approval. Since then there have been notable 
developments in the ﬁeld, not least the much wider use of stated preference methods 
such as conjoint analysis. METHODS: ISPOR’s Patient Preference Conjoint Analysis 
Working Group convened a team to develop a new taxonomy to characterise the dif-
ferent approaches used to capture patient based data. A thorough review of different 
patient reported methods was undertaken, and based upon discussion and further 
expert review, a taxonomy of methods based was developed. RESULTS: Several 
groups of methods emerged from the review which reﬂected both the underlying data 
that the method produces and also the audience of the data—regulators, payers, policy 
makers and decision makers. Group 1 (Classic PRO) includes different psychometric 
approaches, commonly based upon Likert scale responses. This group includes meas-
ures of HRQL, symptoms and treatment satisfaction. Group 2 (Stated preference) 
describes ordinal methods including conjoint analysis (discrete choice, graded 
pairs)and willingness to pay methods. Group 3 (Cardinal utility) describes cardinal 
methods of capturing health outcomes often used in economic evaluation. Each group 
of methods also has naturally different audiences. CONCLUSIONS: The FDA’s simple 
classiﬁcation of measures as PROs does not reﬂect the diversity and applications of 
patient reported data. The proposed taxonomy we believe reﬂects important differ-
ences in methods and also the different uses of data.
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THE EVOLVING HEALTH ECONOMICS EVALUATION PARADIGM AND 
THE ROLE OF THE QALY
Schlander M1, Richardson J2
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The quality-adjusted life year (QALY) is a unit of measurement which combines the 
length and quality of life in a way which reduces the number of dimensions which 
must be taken into account in an economic evaluation. In simple cost utility analysis 
(CUA) the problem of allocating scarce resources is reduced to two steps: ranking 
projects by their cost per QALY and deciding upon a threshold cost per QALY above 
which projects will not be funded. Over time there has been increasing dissatisfaction 
with the perceived excessive simplicity of the approach. Partly this has arisen over 
technical questions: which instrument should be used to measure QALYs (the SG, 
TTO, etc.); should the QALY be replaced by the healthy-year equivalent (HYE)—is 
there additive separability between health states; are valid QALY league tables achiev-
able. However there has been also increased questioning of the value basis of the 
QALY. Should ‘utility’ incorporate an individual or social perspective (like the person 
trade-off, PTO); should economics revert to the earlier concept of hedonic, rather than 
preference / utility (i.e., subjective well-being), but, perhaps most fundamentally, can 
QALYs be abstracted from other values relating to the distribution of beneﬁts between 
patients with dissimilar problems, and disregard characteristics of services except 
when they impact upon utility, social well-being (SWB) or some other uni-dimensional 
value. Apart from normative concerns, there are an increasing number of empirical 
studies on societal preferences for health care resource allocation, indicating that the 
QALY maximization hypothesis must be considered as falsiﬁed. The broad range of 
documented ‘contextual’ variables implies that a uniform ‘social value’ of a QALY 
does not exist, and suggests that projects designed to determine the dollar value of a 
QALY will either fail or mislead policy.
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DEVELOPMENT OF THE ACCEPT© QUESTIONNAIRE TO ASSESS 
ACCEPTABILITY OF LONG TERM TREATMENTS: QUALITATIVE STEPS
Marant C1, Spizak C1, Longin J2, Marrel A1, Van Ganse E3, Arnould B1, Patrick DL4
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OBJECTIVES: Patient-Reported Outcomes (PRO) are routinely used to measure 
disease severity, perceived treatment impact, or patient attitude toward treatment. 
However, adherence can only partially be explained by clinical and these PRO varia-
bles alone. Our objective was to develop a generic Acceptability measure assessing 
how patients balance out between advantages and disadvantages of long-term treat-
ments. It could be used in future adherence studies. METHODS: A literature review 
was conducted in biomedical databases using keywords related to acceptability, per-
ceptions, motivations and barriers linked to treatment, allowing the initial conceptual 
model of Acceptability to be developed. Exploratory interviews were performed with 
5 pharmacists and 18 patients. They were recorded, transcribed word-for-word and 
systematically analysed in order to complete the initial conceptual model. Items of the 
ACCEPT© questionnaire were generated in French for each concept identiﬁed, using 
patients’ words. The resulting test version was tested for relevance and comprehension 
with 5 patients, and revised accordingly; the new version was tested on a second set 
of 5 patients and revised to create the pilot version of the ACCEPT© questionnaire. 
RESULTS: In the test version, items generated for each concept identiﬁed were organ-
ised into 6 sections: drug characteristics, duration, constraints, side-effects, efﬁcacy 
and global acceptability of treatment. Except a few items that were modiﬁed or deleted 
following patients’ suggestions and some minor modiﬁcations in the answer choices, 
the questionnaire was globally very well accepted, easy to complete, and considered 
relevant and appropriate by patients. The pilot version of the ACCEPT© questionnaire 
contains 32 questions divided into the same 6 sections as the test version. CONCLU-
SIONS: The comprehension tests conﬁrmed the existence of the previously hypothe-
sised concept of treatment Acceptability. The ACCEPT© questionnaire will allow the 
Acceptability of a great variety of long-term treatments to be assessed, while being a 
speciﬁc instrument making sense to each individual.
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DIFFERENT STUDY RESULTS OF UTILITIES IN RELATION TO THE 
DOCUMENTING METHOD USED AND THE GUARANTEE OF LEGALLY 
COMPLIANT IQWIG RECOMMENDATIONS WITHIN THE FRAMEWORK 
OF A COST-BENEFIT ASSESSMENT
Dintsios CM, Volz F, Seidl A
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OBJECTIVES: The Institute for Quality and Efﬁciency in Health Care (IQWiG) 
assesses the beneﬁt and costs of drugs by considering their affordability and reasona-
bleness from the insurants’ viewpoint. IQWiG forwards its assessments to the German 
Federal Joint Committee (G-BA) in the form of recommendations, which may be used 
in establishing ceiling prices for drug innovations. Within the framework of its 
methods proposal, IQWiG does not negate an intra-indication-related application of 
QALYs for cost-beneﬁt assessments. However, depending on the methods applied and 
the target populations surveyed, different results can be generated for evaluating states 
of health. No international standard exists for a preferred method. METHODS: After 
performing a systematic literature search to identify studies in which various methods 
for documenting beneﬁt were applied and different target populations were investi-
gated, selected studies are presented, whose incremental cost-utility-ratios have an 
(extremely) wide scatter related to the documenting. Depending on the documenting 
method, indication-dependent trends are investigated for effect size and direction of 
QALYs. RESULTS: The studies identiﬁed show that the variation in methods for 
documenting QALYs even within the same intervention trial considerably reduces its 
comparability. It is also not easily possible for decision-makers to make a decision 
based on these results. The documenting methods used clearly create different con-
structs that apparently display different levels of responsiveness in the same indication 
(e.g. rheumatoid arthritis, sleep apnoea, macular degeneration, oral anticoagulation). 
In the inter-indication comparison, a clear trend could not be determined for the effect 
size in the results in relation to the documenting methods used. CONCLUSIONS: If 
the legal conditions are satisﬁed and a consistent decision using cost-utility analyses 
in one indication area is possible, the documenting method for utilities must be 
standardised. This could be directed indication-speciﬁc towards an optimum corre-
spondence with the responsiveness of validated, disease-speciﬁc quality of life docu-
menting instruments.
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MAKING SUPPORT IN METASTATIC CANCER ? A LITERATURE REVIEW 
AND FRENCH EXPERT OPINIONS
Baffert S1, Alfonsi A2, Florentin V2, Livartowski A1
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Conventional health economic tools are not adapted to the very speciﬁc problems of 
metastatic cancer treatment. The objective of this study was to analyze the methodo-
logical tools used in published economic evaluations for metastatic breast cancer 
(empirical studies) and for all metastatic cancer treatments (methodological studies). 
Results of a systematic literature search (Medline, Embase, Cochrane Library, Pascal, 
HTA databases) since 1990 were completed by expert interviews (oncologists, health 
economists, decision-makers). 535 abstracts were screened and 80 selected, excluding: 
clinical trials with no economic analysis, alternative treatments to chemotherapy, early 
stages of cancer, any metastatic cancer with no speciﬁc and/or original methodology 
and/or endpoints. According to a pharmacoeconomic quality checklist, 37 were ana-
lyzed. The review showed a majority of studies in breast cancer with low level of evi-
dence and only two prospective studies. More than half of the studies were cost-utility 
analyses. Endpoints combine quality of life and other indicators: QALY (Quality-
Adjusted Life Years), Q-TWiST (Quality-Adjusted Time Without Symtoms and Toxic-
ity), QAPFYs (Quality-Adjusted Progression-Free life Years), QADs (Quality-Adjusted 
Days of life). We did not ﬁnd any speciﬁc criterion to the metastatic state. Experts 
recommend the use of multi-dimension criteria comprising direct and indirect costs, 
efﬁcacy and quality of life data integrating patient preferences; thresholds of resource 
allowance should be deﬁned according to treatment strategies and population sub-
groups (performance status, age, illness severity). This study underlines the need to 
develop tools for poor prognosis diseases and raises the issue of the integration of 
economic rationality in the health care decisions in France. Although some countries 
have chosen arbitrations (QALY, Efﬁciency Frontier per pathology), France has not 
yet chosen a validated method for resources allocation.
